Contrast-enhanced MR imaging of the liver: Comparison between Gd-BOPTA and mangafodipir

Journal of Magnetic Resonance Imaging

Volumn 7, Issue 1, 1997, Pages 130-135

  Schima, Wolfgang ^a,b   Petersein, Jan ^a   Hahn, Peter F ^a   Harisinghani, Mukesh ^a   Halpern, Elkan ^a   Saini, Sanjay ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Contrast enhancement; Contrast media, effects; Gadolinium; Liver, MR; Manganese

Indexed keywords

GADOBENIC ACID; MANGAFODIPIR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL NOISE RATIO;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CHELATING AGENTS; CONTRAST MEDIA; EDETIC ACID; FEMALE; HUMANS; IMAGE ENHANCEMENT; INFUSIONS, INTRAVENOUS; LIVER; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; SENSITIVITY AND SPECIFICITY;

EID: 0031421966     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.1880070118     Document Type: Article

References (21)

1. Rosati G, Pirovano G, Spinazzi A. Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 1994; 29(Suppl):S183-S185.
2. Mitchell DG. Focal hepatic lesions: the continuing search for the optimal MR imaging pulse sequence(s). Radiology 1994; 193: 17-18.
3. Crook LE, Hoenninger J, Arakawa M, et al. High-resolution magnetic resonance imaging: technical concepts and their implementation. Radiology 1984; 150:163-171.
4. Edelstein WA, Bottomley PA, Hart HR, Smith LS. Signal, noise, and contrast in nuclear magnetic resonance (NMR) imaging. J Comput Assist Tomogr 1983; 7:391-401.
5. Hendrick RE, Nelson TR, Hendee WR. Optimizing tissue contrast in magnetic resonance imaging. Magn Reson Imaging 1984; 2:193-204.
6. Hahn PF, Weissleder R, Stark DD, Saini S, Elizondo G, Ferrucci JT. MR imaging of focal splenic tumors. AJR 1988; 150:832-827.
7. Bernardino ME, Young SW, Lee JKT, Weinreb JC. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 1992; 183:53-58.
8. Winter TC, Freeny PC, Nghiem HV, et al. MR imaging with IV superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions. AJR 1993; 161:1191-1198.
9. Saini S, Edelman RR, Sharma P, et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR 1995; 164:1147-1152.
10. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792.
11. Pavone P, Patrizio G, Buoni C, et al. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. Radiology 1990; 176: 61-64.
12. Kreft BP, Tanimoto A, Stark DD, et al. Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats. JMRI 1993; 3:41-49.
13. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine: a new contrast agent for MR imaging - preliminary evaluation in healthy volunteers. AJR 1992; 158:887-892.
14. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxy-propionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology 1996; 199:513-520.
15. Cavagna FM, Marzola P, Dapra M, et al. Binding of gadobenate dimeglumine to proteins extravasated into interstitial space enhances conspicuity of reperfused infarcts. Invest Radiol 1994; 29(Suppl):S50-S53.
16. Vogl TJ, Hamm B, Schnell B, et al. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images. JMRI 1993; 3:51-58.
17. Liou J, Lee JKT, Borrello JA, Brown JJ. Differentiation of hepatomas from nonhepatomatous masses: use of Mn-DPDP-enhanced MR images. Magn Reson Imaging 1994; 12:71-79.
18. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996;199:177-183.
19. Mahfouz A-E, Hamm B, Wolf K-J. Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology 1994; 190:49-52.
20. Rummeny E, Wiesmann W, Menker S, Lodemann K, Peters PE. Value of delayed Mn-DPDP-enhanced MR imaging in the detection and differential diagnosis of hepatic tumors. JMRI 1992; 2(P):64-65.
21. Rofsky NM, Weinreb JC, Bernardino ME, Young SW, Lee JKT, Noz ME. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. Radiology 1993; 188:53-59.